Tirofiban plus aspirin for moderate ischemic stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether combining a blood-thinning drug (tirofiban) with aspirin can improve recovery after a moderate stroke that started within the last 24 hours. It aims to see if this combination is safe and helps more than aspirin alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You had an ischemic stroke (blockage in the brain) within the last 24 hours.
- Your stroke must be mild to moderate in severity (NIHSS score 4-10).
- You must be able to move your arm or leg at least a little (score of 1 or more on arm or leg strength).
- You must not have had bleeding in the brain, and you must not be planning to have clot-busting or clot-removal treatment.
- You must be able to take aspirin and tirofiban and have no allergies to them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug tirofiban (a blood thinner) to prevent another stroke in people who have had a mild stroke or high-risk TIA and have a narrowed artery in the brain. It must be started within 24 hours of symptoms.
This trial tests whether a combination of a clot-preventing drug (tirofiban) followed by two antiplatelet drugs (aspirin and clopidogrel) can improve recovery in people who have had a mild stroke. It aims to find a better way to prevent further strokes or worsening symptoms.
This trial tests adding the anti-clotting drug tirofiban to standard clot removal for people who have a stroke due to a narrowed artery in the brain. The goal is to see if this combination improves outcomes without raising bleeding risk.
This trial tests a medication called tirofiban given intravenously after standard thrombolysis to see if it improves recovery in people with acute ischemic stroke. It is for those whose symptoms have not improved or are getting worse after initial treatment.
This trial tests whether adding a second medicine (tirofiban) to standard clot-busting treatment can help people who are not improving after the first hour. It is for people with a moderate to severe stroke who are not candidates for a clot-removal procedure.
This trial tests whether giving tirofiban (a blood thinner) shortly after the standard clot-busting drug tenecteplase can improve recovery from a moderate stroke. It is for people who have had a stroke within the last few hours and do not have certain risk factors like irregular heart rhythm or recent bleeding.
Hear when a new Ischemic Stroke, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.